Spero Therapeutics Inc (SPRO) USD0.001
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.